ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1883

Auto-antibodies Targeting Membrane Repair Proteins Enhances Myositis Phenotype

Shane Bruckner1, Kassidy Banford2, hannah Bulgart2, Kevin mcElhanon3, Rohit Aggarwal4, Chester Oddis5, Noah Weisleder1 and Wael Jarjour1, 1The Ohio State University, Columbus, OH, 2The Ohio State University Wexner Medical Center, Columbus, OH, 3Pfizer Inc., Cambridge, MA, 4Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, 5University of Pittsburgh, Pittsburgh, PA

Meeting: ACR Convergence 2022

Keywords: Autoantibody(ies), Mouse Models, Other, Muscle Biology, Myositis

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2022

Title: Muscle Biology, Myositis and Myopathies Poster II

Session Type: Poster Session D

Session Time: 1:00PM-3:00PM

Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a group of disorders in which autoimmune responses produce a chronic state of inflammation resulting in degeneration of skeletal muscle structure and function. Our previous work generated a robust model of inflammatory myositis by combining a mouse with impaired sarcolemmal membrane repair synaptotagmin VII (SytVII)-/- with a mouse with a regulatory T cell deficiency FoxP3-/Y . The sarcolemmal membrane repair response is a conserved response necessary to restore membrane integrity in myocytes in a variety of muscle diseases. Previous work helped identify TRIM72/MG53 and dysferlin proteins as critical components of the membrane repair process. Our current studies address if antibodies against TRIM72/MG53 contribute to the progression of myositis.

Methods: Levels of antibodies against repair proteins were measured in FoxP3-/Y/SytVII-/-mouse model and dermatomyositis and polymyositis patient serum samples with custom ELISA. Membrane repair function was determined using mechanical glass bead wounding or multi-photon infrared laser microscopy to damage the cell membrane of muscle fibers and live cell imaging to record the entry of fluorescent FM4-64 dye. We also measured membrane integrity in vivo through the use of IgG immunostaining of muscle histology sections. Additionally, we injected exogenous antibodies against membrane repair proteins into myositis mice and determined changes to the myositis phenotype in vivo.

Results: Our results identified novel autoantibodies against membrane repair proteins in IIM patient serum and that exogenous antibodies against these proteins can compromise membrane repair in isolated healthy muscles. Moreover, the injection of antibodies against membrane repair into adoptive transfer myositis mice demonstrated a significant enhancement of the myositis phenotype compared to normal IgG injections. The adoptive transfer of lymph nodes from our FoxP3-/y/SytVII-/- mice into a Rag1-/- mouse background demonstrated that sarcolemmal repair is significantly compromised in distal skeletal muscle in the absence of inflammation, suggesting that these antibodies are sufficient to compromise membrane repair. Additional studies show that IIM patient serum with a high titer of TRIM72 antibodies can also compromise membrane repair in healthy muscle ex vivo.

Conclusion: These findings represent a novel mechanism in IIM whereby decreased sarcolemma integrity induces a vicious cycle of aberrant antigen presentation that directly contributes to the pathophysiology of idiopathic immune myopathies.

Supporting image 3

Anti-TRIM72 Antibodies Enhance Skeletal Muscle Inflammation


Disclosures: S. Bruckner, None; K. Banford, None; h. Bulgart, None; K. mcElhanon, None; R. Aggarwal, Mallinckrodt, Bristol Myers Squibb, EMD Serono, Pfizer, Octapharma, CSL Behring, Q32, Kezar, AstraZeneca, Alexion, Argenx, Boehringer Ingelheim, Corbus, Janssen, Kyverna, Roivant, AbbVie, Jubilant, Orphazyme, Genentech; C. Oddis, None; N. Weisleder, TRIM-edicine, Myofinity, Casma Therapeutics, Nido Biosciences; W. Jarjour, None.

To cite this abstract in AMA style:

Bruckner S, Banford K, Bulgart h, mcElhanon K, Aggarwal R, Oddis C, Weisleder N, Jarjour W. Auto-antibodies Targeting Membrane Repair Proteins Enhances Myositis Phenotype [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/auto-antibodies-targeting-membrane-repair-proteins-enhances-myositis-phenotype/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/auto-antibodies-targeting-membrane-repair-proteins-enhances-myositis-phenotype/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology